[go: up one dir, main page]

CA2657946A1 - Toxines proteiques modifiees ciblant des cellules porteuses du recepteur des cytokines et leur utilisation pour le traitement d'une maladie - Google Patents

Toxines proteiques modifiees ciblant des cellules porteuses du recepteur des cytokines et leur utilisation pour le traitement d'une maladie Download PDF

Info

Publication number
CA2657946A1
CA2657946A1 CA002657946A CA2657946A CA2657946A1 CA 2657946 A1 CA2657946 A1 CA 2657946A1 CA 002657946 A CA002657946 A CA 002657946A CA 2657946 A CA2657946 A CA 2657946A CA 2657946 A1 CA2657946 A1 CA 2657946A1
Authority
CA
Canada
Prior art keywords
cytokine
pore
forming protein
protein toxin
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002657946A
Other languages
English (en)
Inventor
James Thomas Buckley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protox Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2657946A1 publication Critical patent/CA2657946A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002657946A 2006-06-09 2007-06-11 Toxines proteiques modifiees ciblant des cellules porteuses du recepteur des cytokines et leur utilisation pour le traitement d'une maladie Abandoned CA2657946A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80441306P 2006-06-09 2006-06-09
US60/804,413 2006-06-09
PCT/CA2007/001018 WO2007140618A1 (fr) 2006-06-09 2007-06-11 Toxines protéiques modifiées ciblant des cellules porteuses du récepteur des cytokines et leur utilisation pour le traitement d'une maladie

Publications (1)

Publication Number Publication Date
CA2657946A1 true CA2657946A1 (fr) 2007-12-13

Family

ID=38801023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002657946A Abandoned CA2657946A1 (fr) 2006-06-09 2007-06-11 Toxines proteiques modifiees ciblant des cellules porteuses du recepteur des cytokines et leur utilisation pour le traitement d'une maladie

Country Status (2)

Country Link
CA (1) CA2657946A1 (fr)
WO (1) WO2007140618A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031185A1 (fr) * 2008-09-19 2010-03-25 Protox Therapeutics Inc. Traitement de cellules souches cancéreuses à l'aide de protéines cargo ciblées

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278279B2 (en) 2008-12-15 2012-10-02 Protox Therapeutics Corp. Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
EP2701686A4 (fr) 2011-04-28 2014-11-05 Stc Unm Bicouches lipidiques supportées sur des nanoparticules poreuses (protocellules) pour l'administration ciblée, et procédés d'utilisation associés
WO2013103614A1 (fr) * 2011-12-30 2013-07-11 Stc.Unm Peptides de liaison à crlf-2 ; proto-cellules et particules de type viral utiles dans le traitement du cancer, comprenant la leucémie lymphoblastique aiguë (all)
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
WO2020068798A1 (fr) 2018-09-24 2020-04-02 Guo Jimin Cellules de mammifère vivant modifiées avec des nanoparticules modulaires fonctionnelles
WO2020176716A1 (fr) 2019-02-28 2020-09-03 Brinker C Jeffrey Compositions de super-assemblage de polyèdre organométallique modulaire
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
EP0753071A1 (fr) * 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Agents porogenes lytiques cibles sur des cellules
US7947289B2 (en) * 2004-02-09 2011-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
CN101238145B (zh) * 2005-06-14 2013-04-24 普罗陶克斯有限公司 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031185A1 (fr) * 2008-09-19 2010-03-25 Protox Therapeutics Inc. Traitement de cellules souches cancéreuses à l'aide de protéines cargo ciblées

Also Published As

Publication number Publication date
WO2007140618A1 (fr) 2007-12-13

Similar Documents

Publication Publication Date Title
CA2657946A1 (fr) Toxines proteiques modifiees ciblant des cellules porteuses du recepteur des cytokines et leur utilisation pour le traitement d'une maladie
US20200283498A1 (en) T cell receptor fusions and conjugates and methods of use thereof
AU714541B2 (en) IL-13 receptor specific chimeric proteins and uses thereof
Waldmann The IL-2/IL-2 receptor system: a target for rational immune intervention
US20160271231A1 (en) Treating cancer stem cells using targeted cargo proteins
US12419934B2 (en) Molecular signature of cancer
US6518061B1 (en) IL-13 receptor specific chimeric proteins and uses thereof
JP2005507870A (ja) 低毒性のインターロイキン−２突然変異体
US20230272033A1 (en) Epha3 and multi-valent targeting of tumors
Foss DAB389IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology
EP2386639A2 (fr) Proteines toxines formatrices de pores modifiées et leurs utilisations
US20030129132A1 (en) IL-13 receptor specific chimeric proteins & uses thereof
US20210008167A1 (en) T cell receptor fusions and conjugates and methods of use thereof
Kawakami et al. Cytotoxins and immunotoxins for cancer therapy: clinical applications
WO2003031474A2 (fr) Cd137 en tant que facteur de proliferation pour cellules souches hematopoietiques
EP1999269A2 (fr) Éphrine-a1 monomère soluble
Debinski Molecular targeting of brain tumors with cytotoxins: Novel bacterial toxin-containing anti-brain tumor therapeutics
Kreitman IBC’s International Conference on novel therapeutic proteins for oncology (drug discovery and development)

Legal Events

Date Code Title Description
FZDE Dead